Detailed price information for Galectin Therapeutic (GALT-Q) from The Globe and Mail including charting and trades.

Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin’s Phase 3 path and clarifies regulatory endpoints. The FDA’s endorsement of a single, well-controlled Phase 3 trial with ...

The HYPCON 3 Trial: A phase II/III randomized study evaluating hypo-fractionated accelerated versus conventional fractionated adjuvant radiation therapy in head and neck malignancies.

Shares of Galectin Therapeutics surged after the company said it was preparing for a Phase 3 trial of its liver disease treatment following a positive meeting with the Food and Drug Administration.

An international research team developed a triple-junction all-perovskite solar cell using a graphene oxide ...

Mutations to the protein SPOP are widespread in cancer, yet many remain poorly understood. To address this gap, St. Jude ...

Disorders of gut–brain interaction, such as irritable bowel syndrome and functional dyspepsia, are increasingly linked to ...

Paradox Interactive’s grand strategy games are known for their uncompromising scope and depth in recreating entire eras of history, but never before have they attempted something quite so dizzyingly ...

Researchers working with data from the South Pole Telescope have released a major catalog of galaxy clusters, giving ...

With nearly two decades of retail management and project management experience, Brett Day can simplify complex traditional and Agile project management philosophies and methodologies and can explain ...

Sixty-nine organisations have proactively published their 2025 animal research statistics including the University of Glasgow. UAR has also produced a list of 69 organisations in ...